Study Evaluates Alopecia Areata Features in Hispanic Population Study Evaluates Alopecia Areata Features in Hispanic Population
In the study, the most common comorbidity in patients overall was atopy, including allergic rhinitis, asthma, and/or atopic dermatitis.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 29, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Rhinitis Patients Report Symptomatic Medication Use Rhinitis Patients Report Symptomatic Medication Use
A mobile app used to capture control of allergic rhinitis may favor those who are more tech savvy, say critics.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms? Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms?
Adding tezepelumab to cat allergy shots may provide better, longer-lasting symptom relief than allergy shots alone for patients with allergic rhinitis due to cat allergens, researchers report.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 18, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Immunotherapy for Allergic Rhinitis and Asthma Has Lasting Effects Immunotherapy for Allergic Rhinitis and Asthma Has Lasting Effects
Allergen immunotherapy for allergic rhinitis and asthma is effective long-term, according to real-world evidence and real-world data, researchers in Europe report.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 14, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Mayo Clinic Q and A:  Sinusitis and treatment options
DEAR MAYO CLINIC: I have had ongoing nasal congestion and mucus for the past several months. I thought it was allergies, but my doctor says I likely have acute sinusitis brought on by allergic rhinitis. I was advised to try nonprescription medications to relieve my symptoms rather than antibiotics. What is the difference between this and a normal sinus infection, and what are the best treatment options? ANSWER: Acute sinusitis causes the spaces inside your nose —… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 2, 2022 Category: Databases & Libraries Source Type: news

Mayo Clinic Minute: How to get hay fever relief from fall allergies
Autumn is the season of change, with green leaves turning color and temperatures cooling. It's also the season of hay fever, or allergic rhinitis. So how can people with fall allergies get relief? Watch: The Mayo Clinic Minute https://youtu.be/0OEAj1x6L-o Journalists: Broadcast-quality video (1:06) is in the downloads at the end of this post. Please courtesy: "Mayo Clinic News Network." Read the script. "Fall is a very common season for seasonal allergies to kick in," says… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 27, 2022 Category: Databases & Libraries Source Type: news

New Nasal Spray for Seasonal Allergic Rhinitis New Nasal Spray for Seasonal Allergic Rhinitis
Patients with both nasal and ocular symptoms of SAR have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 7, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Miracle ‘farm dust’ pill could prevent childhood allergies
Treatments based on barnyard material and unprocessed milk may be developed by 2027An international team of scientists is working on a “farm dust” treatment to stop childrendeveloping allergies as research reveals the protective benefits of being brought up on a farm can last into adulthood.The study has found evidence that children brought up on family farms have greater protection into early adulthood from allergic rhinitis, a reaction that can cause a runny nose, sneezing and red eyes.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 4, 2022 Category: Science Authors: Jon Ungoed-Thomas Tags: Allergies Medical research Health Science Source Type: news

Glenmark's partner Hikma launches specialty drug Ryaltris in US
Ryaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. Glenmark developed the drug, while Hikma will commercialise it in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2022 Category: Pharmaceuticals Source Type: news

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news

One-Third of YouTube Hay Fever Videos Are Misleading
THURSDAY, Aug. 18, 2022 -- Less than half of YouTube videos on allergic rhinitis provide useful information, according to a study published online July 13 in the Annals of Allergy, Asthma& Immunology. Celine Lund-Nielsen Remvig, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 18, 2022 Category: Pharmaceuticals Source Type: news

Looking for Reliable Hay Fever Advice? It's Probably Not on YouTube
TUESDAY, Aug. 16, 2022 -- Need information about hay fever? Steer clear of YouTube, a new study advises. Researchers found misinformation about allergic rhinitis, the medical name for the disorder, in a large numbers of posts on the popular... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 16, 2022 Category: General Medicine Source Type: news